---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009469"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T19:10:52.842232+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioAtla reports FY2022 net loss $106.5M, cash $215.5M; advances CAB-ADC and bispecific trials

## Summary
- Net loss Q4 2022 $27.5M, full year $106.5M, vs Q4 2021 $23.4M and FY2021 $95.4M.
- R&D expenses FY2022 $79.3M, up from $58.3M in FY2021, driven by clinical development.
- Cash $215.5M at year-end 2022; expected to fund operations into 2025.
- Cleared DLT for BA3011 dose-intensive schedule; LMS readout 2H23; UPS registrational Phase 2 start in 1H23.
- FDA cleared IND for BA3182 (CAB-EpCAMxCD3 TCE); FPI Phase 1 in 1H23. BA3021 NSCLC and BA3071 Phase 2 data in 2H23.

## SEC filing metadata
- accession: 0000950170-23-009469
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017023009469/0000950170-23-009469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017023009469/bcab-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009469
- JSON: https://secwatch.observer/filing/0000950170-23-009469.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009469.txt

## Key facts
- Earnings Releases
  BioAtla, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
  - Period: the fourth quarter and fiscal year ended December 31, 2022
  - Result: reported results
  source text: On March 23, 2023, BioAtla, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000095017023009469/0000950170-23-009469-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.